Lee’s Pharm Supports Disaster Relief Efforts for Wang Fuk Court in Tai Po

- Writer

Senin, 1 Desember 2025 - 10:46 WIB

facebook twitter whatsapp telegram line copy

URL berhasil dicopy

facebook icon twitter icon whatsapp icon telegram icon line icon copy

URL berhasil dicopy

HONG KONG, Dec. 1, 2025 /PRNewswire/ — Lee’s Pharmaceutical Holdings Limited ("Lee’s Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court in Tai Po, which caused multiple casualties and left many residents homeless and in urgent need of assistance. The Group has made a donation of HK$200,000 to the "Support Fund for Wang Fuk Court in Tai Po" established by the HKSAR Government to render assistance to residents of Wang Fuk Court and support all relevant works.

As a pharmaceutical company listed in Hong Kong for over two decades, Lee’s Pharm deeply mourns the victims of the fire and extends heartfelt sympathy to those injured and the families affected. During this difficult time, the Group stands in solidarity with the people of Hong Kong, committing to support those impacted through concrete actions. We also call on all sectors of society to join hands in helping the victims overcome this hardship and rebuild confidence in their lives.

The Group also pays the highest tribute to the firefighters, medical staff, and volunteers who have worked tirelessly and bravely in the rescue efforts and expresses profound gratitude for their selfless dedication and perseverance.

About Lee’s Pharmaceutical Holdings Limited

Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with over 30 years of operation in the pharmaceutical industry in China. The company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales, and marketing based in Mainland China with global perspectives. Lee’s Pharm has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic, and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau, and Taiwan. The company focuses on several key disease therapeutic areas such as cardiovascular health, woman’s health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. For more information about Lee’s Pharm, please visit: www.leespharm.com.

 

Berita Terkait

AiMOGA Launches Global Robot Innovation: Mobo Debuts from Wuhu, Empowering Homes and Businesses
Seatrium and Karpowership Sign Contract for a Series of Whale Class Powership Conversion and Integration Projects
Seatrium and Karpowership Sign Contract for a Series of Whale Class Powership Conversion and Integration Projects
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
Bonree Advances AI-Native Observability and Global Expansion, Reinforcing Its Leadership in China’s APMO Market
Singapore and Malaysia Lead the Largest AppliedEdu ASEAN Rankings to Date
USS Returns This November, Uniting SEA’s Lifestyle, Fashion & Creative Communities with Malaysian Brands Joining the Line-up
Sungrow Advances Integrated C&I Microgrid Solution to Southeast Asia

Berita Terkait

Jumat, 23 Oktober 2026 - 02:49 WIB

AiMOGA Launches Global Robot Innovation: Mobo Debuts from Wuhu, Empowering Homes and Businesses

Jumat, 23 Oktober 2026 - 00:00 WIB

Seatrium and Karpowership Sign Contract for a Series of Whale Class Powership Conversion and Integration Projects

Jumat, 23 Oktober 2026 - 00:00 WIB

Seatrium and Karpowership Sign Contract for a Series of Whale Class Powership Conversion and Integration Projects

Kamis, 22 Oktober 2026 - 14:35 WIB

HLB Customers Can Now Scan & Pay in China with HLB QR Pay

Kamis, 22 Oktober 2026 - 10:39 WIB

Bonree Advances AI-Native Observability and Global Expansion, Reinforcing Its Leadership in China’s APMO Market

Berita Terbaru

Press Release

HLB Customers Can Now Scan & Pay in China with HLB QR Pay

Kamis, 22 Okt 2026 - 14:35 WIB